These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31130319)

  • 21. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
    Kirschenbaum BE
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
    Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
    Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy.
    Stakišaitis D; Zamarytė-Sakavičienė K; Lesauskaitė V; Jankūnas RJ
    Ther Innov Regul Sci; 2019 Jul; 53(4):549-553. PubMed ID: 30200777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early market access for unauthorized drugs in Italy: The value-based price for reimbursement decisions.
    Maratea D; Venturini F
    Eur J Intern Med; 2016 May; 30():e15-e16. PubMed ID: 26851984
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations.
    Kolasa K; Kalo Z; Zah V
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):483-8. PubMed ID: 27467881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coverage with evidence development for medical devices in Europe: Can practice meet theory?
    Drummond M; Federici C; Reckers-Droog V; Torbica A; Blankart CR; Ciani O; Kaló Z; Kovács S; Brouwer W
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):179-194. PubMed ID: 35220644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing access to orphan medicinal products in Europe.
    Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
    Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.